Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ridgeback Biotherapeutics

- PMLiVE

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

There are no FDA approved vaccines for EBV, one of the most common human viruses

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

- PMLiVE

FDA approves intramuscular administration of Merck’s MMRV vaccines

Until now, the vaccines have only been administered via subcutaneous injection

- PMLiVE

WHO countries begin negotiations on global pandemic preparedness agreement

The discussions will continue over the next year until a final draft is made in 2024

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

FDA authorises first at-home COVID-19 and flu test for emergency use

The single-use test uses nasal swab samples and provides results in about 30 minutes

- PMLiVE

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

Merck KGaA and Aqilion AB partner in potential €960m deal

The companies will work together to develop small molecule inhibitors of the TAK1 protein

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links